You are using an older version of Internet Explorer that is not supported on this site. Please upgrade for the best experience.


Click on a trial to find out the eligibility requirements and who to contact if you have questions about participating.

Page 1 of 1 | Results 1 - 2 of 2

GEMINI 1 - A Phase III multicenter trial evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine (study drugs) compared to dolutegravir plus tenofovir/emtricitabine in HIV-1

The purpose of this study is to compare safety, efficacy, and tolerability of a two drug regimen of dolutegravir (DTG) plus (+) lamivudine (3TC) administered once daily to the DTG plus Tenofovir [TDF]/Emtricitabine [FTC] fixed dose combination [FDC] administered once daily in human immunodeficiency virus (HIV) 1 infected adult subjects that have not previously received antiretroviral therapy. The study is designed to demonstrate the non-inferior antiviral activity of DTG plus 3TC regimen to that of DTG plus TDF/FTC FDC.
Dr. Daniel Skiest
Infection, HIV

Baystate Medical Center
759 Chestnut Street
Springfield, MA 01199

REPRIEVE - Randomized Trial to Prevent Vascular Events in HIV

The purpose of this study is to test the efficacy of 4 mg Pitavastatin daily on cardiovascular-related events among HIV-1 infected adults.

Daniel J. Skiest, MD
HIV, Heart

Baystate Infectious Diseases Clinical Research
3300 Main Street
Springfield, MA 01199

Page 1 of 1 | Results 1 - 2 of 2